Abstract: A system and a method for monitoring anatomical changes in a subject in radiation therapy are provided, as well as an arrangement for medical imaging and analysis and a computer program product for carrying out the method. For monitoring anatomical changes in a subject in radiation therapy, the following steps are performed. First anatomical image data and subsequent anatomical image data of the subject are received. The first anatomical image data and the subsequent anatomical image data are analyzed. This analysis comprises registering the subsequent anatomical data to the first anatomical data. Changes between the first anatomical image data and the subsequent anatomical image data are identified as change states, and the identified change states are matched to corresponding qualitative descriptions. A monitoring report is provided, which comprises the qualitative descriptions of the identified changes.

Abstract: A device for optimizing a radiation therapy plan (30) for delivering therapeutic radiation to a patient using a therapeutic radiation source (16) while modulated by a multi-leaf collimator (MLC) (14) includes at least one electronic processor (25) connected to a radiation therapy device (12). A non-transitory computer readable medium (26) stores instructions readable and executable by the at least one electronic processor to perform a radiation therapy plan optimization method (102) including: optimizing MLC settings of the MLC respective to an objective function wherein the MLC settings define MLC leaf tip positions for a plurality of rows of MLC leaf pairs at a plurality of control points (CPs). The optimizing is performed in two or more iterations with a resolution of the MLC settings increasing in successive iterations.

Abstract: A radiation planning system includes a predictor-corrector optimizer unit which computes a predicted dose based on a collection of control points with a current approximate dose, each control point with a corresponding set of leaf positions, and determines an additional control point with a corresponding set of leaf positions based on a difference of the predicted fluence and the current approximate fluence through a least cost or shortest path in a layered graph structure of realizable leaf positions. Tools are described to help a planner to evaluate the effect of parameter changes to the current plan based on an identified zone of influence. The planner interactively views the current plan based on a visualization of the plan objectives and correlations between the objectives.

Abstract: A method for reviewing a treatment plan including displaying list of at least one of a selected plurality of patients, institutions, and treatment plans associated with a treatment planning system, selecting at least one of the one or more patients, institutions, and treatment plans, querying treatment plan parameters associated with the selected one or more patients, institutions, and treatment plans, and generating a report file of the queried treatment plan parameters

Abstract: A process for reduction and/or removal of FXI and FXIa from a source solution containing said coagulation factors and as main components immunoglobulins comprising the following steps: a) contacting the FXI and/or FXIa containing solution with an affinity chromatographic gel wherein heparin or heparan is linked to the matrix material; b) allowing adsorption of FXI and/or FXIa and c) separation of the liquid deprived of FXI and/or FXIa from the adsorption media.

Abstract: A classification system for systems of n mirrors, whereby systems of mirrors are classified by a number C, is defined as follows: C = ∑ i = 1 n ⁢ a i · 2 ( n - i ) ⁢ ( M &LeftBracketingBar; M &RightBracketingBar; ) where: ai=1 if the angle of incidence of the chief ray at mirror i is negative, ai=0 if the angle of incidence of the chief ray at mirror i is positive, M is the magnification of the projection system, and index i numbers the mirrors of the system in series.

Abstract: A method for the inactivation of viruses, in particular those having no lipid coats, in protein-containing compositions from blood, blood plasma or similar natural sources by treating said source, simultaneously or succesively, with an effective amount of dialkyl or trialkyl phosphates and optionally surfactants at an elevated temperature in the range of from 55° C. to 67° C. for five hours to 30 hours.

Abstract: A two-component fibrin glue for human application includes a) a component A containing i) a virus-inactivated and concentrated cryoprecipitate that contains fibrinogen, and ii) tranexamic acid or a pharmaceutically acceptable salt, thereof; and b) component B containing a proteolytic enzyme that, upon combination with component A, cleaves, specifically, fibrinogen present in the cryoprecipitate of component A, thereby, effecting a fibrin polymer.